FIELD: medicine.
SUBSTANCE: invention concerns medicine, namely to immunology, rheumatology, and concerns pseudorheumatism treatments. For this purpose use autologous T-lymphocytes, activated with the help of anti CD3 antibodies and interleukin-2. Administer activated T-lymphocytes subcutaneously once a week within 4 weeks and further once a month within one year. Simultaneously spend standard therapy using cytostatic preparations.
EFFECT: decrease of clinical implications of disease at expense of impact on changed immune response through induction of antiergotypical response.
2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIOTRANSPLANT AND METHOD FOR TREATMENT OF RHEUMATIC AND AUTOIMMUNE DISEASES | 2005 |
|
RU2298410C1 |
| METHOD FOR TREATMENT OF ANKYLOSING SPONDYLARTHRITIS | 2003 |
|
RU2231356C1 |
| METHOD FOR TREATING RHEUMATOID ARTHRITIS | 2001 |
|
RU2199320C1 |
| METHOD FOR TREATMENT OF PSORIATIC ARTHRITIS | 2003 |
|
RU2228755C1 |
| METHODS OF DIAGNOSING AND TREATING RHEUMATOID ARTHRITIS | 2020 |
|
RU2828027C2 |
| COMPOSITION FOR TREATING DISEASE | 2009 |
|
RU2531548C2 |
| THERAPY OF PATIENTS SUFFERING FROM RHEUMATOID ARTHRITIS WITH APPLYING COMBINATION OF TUMOUR NECROSIS ALPHA FACTOR ANTIBODIES | 2007 |
|
RU2360717C1 |
| METHOD FOR DETERMINING INDICATIONS TO BEGINNING OF RECEPTION OF GENETIC ENGINEERING BIOLOGICAL PREPARATIONS WITH INEFFECTIVENESS OF BASIC ANTI-INFLAMMATORY PREPARATIONS IN EARLY FORMS OF PSORIATIC ARTHRITIS | 2020 |
|
RU2731807C1 |
| METHOD FOR ASSESSING RISK OF SACROILIITIS PROGRESSION IN PATIENTS WITH EARLY PSORIATIC ARTHRITIS | 2024 |
|
RU2837143C1 |
| METHOD OF TREATMENT OF ATOPIC DERMATITIS | 2007 |
|
RU2340348C1 |
